Sanofi Invests in Graviton and its Lead Product, a ROCK2 Inhibitor in-licensed from Beijing Tide

Sanofi, a Paris multinational biopharma focused on novel drugs and vaccines, made an unspecified investment in New York City’s Graviton Bioscience in return for a 12-month right-of-first-refusal to acquire global rights to Graviton’s lead product, a ROCK2 inhibitor. Two years ago, Graviton acquired global (ex-China) rights to the candidate from Beijing Tide Pharma, a Sinopharm subsidiary, in a $518 million deal. Graviton’s GV101 is a selective inhibitor of Rho/Rho-associated coiled-coil containing protein kinase 2 (ROCK2), currently in a Phase I trial. GV101 showed blood-brain-barrier penetration in preclinical tests, and Graviton believes it has best-in-class potential. More details....

Share this with colleagues: